A Hybrid Lifestyle Program and Metabolic Health in Adults With Obesity: The PRAMEV Randomized Clinical Trial
Primary result · ≥5% weight lossResult — go to the resultOdds ratio 1.34 95% CI 0.61–2.92Authors' conclusion
In this randomized clinical trial of 200 adults with obesity receiving care in Brazil's public health care system, a hybrid-format lifestyle intervention did not improve the likelihood of achieving 5% or greater weight loss in the intention-to-treat analysis.
Study context
- Population
- Adults with BMI ≥30, tertiary public hospital in São Paulo, Brazil; mean age 47.9 years, 86.0% womenrandomized 1:1
- Participants
- 200 adults
- Comparison
- PRAMEV plus usual care vs usual medical care alone
- PRAMEVn = 97
- Controln = 103reference
- Primary endpoint
- Proportion achieving ≥5% reduction in body weight (bioelectrical impedance analysis)
- Follow-up
- 20 weeks
Methodological detailsopen-label, parallel-group, superiority, single-centre
- Open-label
- Parallel-group
- Superiority
- Single-centre
Primary result
≥5% weight loss
Odds ratio
1.34
95% CI 0.61–2.92
P = 0.46
Events by treatment group
PRAMEVvs Control
OR 1.34 (95% CI 0.61–2.92); P = 0.46
As reported in the abstract
Secondary outcomes
Dropout · 20 weeks
P = 0.008
- Dropout: 143 participants (71.4%) completed follow-up
Weight loss and anthropometric outcomes
- Greater weight loss and improved anthropometric outcomes with PRAMEV
- Per-protocol analysis
Lipid profile and liver enzymes
- Improved lipid profile, with reductions in liver enzyme and TG levels and favorable changes in cholesterol fractions
Safety
- No serious adverse events were reported
Original publication
A Hybrid Lifestyle Program and Metabolic Health in Adults With Obesity: The PRAMEV Randomized Clinical Trial. JAMA Netw Open. Published 3 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →